aTyr Pharma, Inc. (ATYR) News
Track canonical SquawkNews coverage tagged to ATYR, aTyr Pharma, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 3 indexed stories across 2 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
aTyr Pharma, Inc. (ATYR) Aligns With FDA on Phase 3 Efzofitimod Study
aTyr Pharma aligned with FDA on a global Phase 3 protocol for efzofitimod in pulmonary sarcoidosis using FVC at week 48 as the primary endpoint; study activities are expected to begin in Q4 2026 and will require addition
REGULATION | Sep 24, 2026, 10:01 AM UTC
L
ATYR - aTyr Pharma Announces Alignment with FDA on Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis
ATYR - aTyr Pharma Announces Alignment with FDA on Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis
REGULATION | Sep 24, 2026, 10:00 AM UTC
L
aTyr Pharma updates timing for Phase 3 efzofitimod study response
aTyr Pharma said it will provide an update on the timing of the regulatory response for its planned Phase 3 study of efzofitimod in pulmonary sarcoidosis.
EQUITY | Sep 01, 2026, 08:40 PM UTC